CLINICAL TRIAL

Effect of Psilocybin Only and Psilocybin Assisted Cognitive Behavioral Therapy in the Management of Major Depressive Disorder and Associated Metabolic, Immune, Inflammatory, Neuroplasticity and Electrical Activity Markers: a Randomized Controlled Trial

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: ClinicalTrials.gov
Date: 2025-09-02
Source: ClinicalTrials.gov
DOI: Unavailable
PubMed: Unavailable

Authors

Khyber Medical University Peshawar

Watch author

Derived topics and classifications

psilocybin psilocin Depression Neuroplasticity Brain Imaging Biomarkers Clinical Trial Randomized Controlled Trial Inflammation Immune Function Randomized Controlled Trial

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

Engaging Mood Brain Circuits with Psilocybin (EMBRACE): a study protocol for a randomized, placebo-controlled and delayed-start, neuroimaging trial in depression.Trials · 2024-07-03 Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin (NECTAR) in Aging and Alzheimer's DiseaseClinicalTrials.gov · 2026-08-07 Psilocybin Versus Ketamine - Fast Acting Antidepressant Strategies in Treatment-resistant DepressionClinicalTrials.gov · 2022-05-20 A One-Year Observational Follow-up Study of Participants With Major Depressive Disorder Following a Randomized, Double-Blind Single-Dose of Psilocybin or Niacin-ControlClinicalTrials.gov · 2026-05-04 A Phase III, Multicentre, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10 A Randomized, Double-Blind Study of Single-Dose Psilocybin for Major Depressive Disorder (MDD)ClinicalTrials.gov · 2026-04-22 S1 Appendix - Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trialFigshare · 2025-09-19 A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive DisorderClinicalTrials.gov · 2025-08-19